Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
Keywords: Selective PPARα modulator; Pemafibrate; K-877; Triglycerides; Dyslipidemia; Liver dysfunction; Fatty liver; Homocysteine; Renal dysfunction; Fibrates;